Eris Lifesciences Limited was incorporated as a private limited company under the name Eris Lifescience Private Limited on January 25 2007. Subsequently the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9 2007. Further the company was converted into a public limited company and the name was changed to 'Eris Lifesciences Limited' on February 2 2017.The company develops manufactures and commercialize branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM) such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.In 2007 the company launched Eris division focused on cardiology and diabetes segment. In 2008 the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009 the company launched Adura division focused on cardiology and diabetes segment. In 2011 the company launched Montana division focused on gynecology and pediatrics segment. In 2012 the company launched Inspira division focused on cardiology segment. In 2014 the company launched Victus division focused on anti-diabetes segment. During the year the company set up manufacturing facility at Assam. In 2015 the company launched Eris 2 division focused on pain management segment.In 2016 the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now Aprica Pharmaceuticals Private Limited). During the year the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017 the company acquired the trademarks `UNION' `REUNION' and `BON UNION'.Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603.In October 2017 Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 12.85 crore. UTH is largely engaged in the segments of Obesity Diabetes Gestational diabetes mellitus Maternal nutrition and Cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.In November 2017 Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 500 crore. With this acquisition Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology Psychiatry Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.